ADC Therapeutics SA Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised
ADC Therapeutics SA (ADCT) had Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised of $901.34 million as of 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Notes › Income Taxes
ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised · last filed 2023-03-15
- 2022-12-31: Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised $901.34M.
- 2021-12-31: Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised $779.47M.
- 2020-12-31: Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised $589.00M.
- 2019-12-31: Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised $448.06M.
| Period end | Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised |
|---|---|
| 2022-12-31 | $901.34M 20-F · filed 2023-03-15 |
| 2021-12-31 | $779.47M 20-F · filed 2023-03-15 |
| 2020-12-31 | $589.00M 20-F · filed 2022-03-17 |
| 2019-12-31 | $448.06M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |